Dr. Robert M. Jackson, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Boston University School of Medicine (1976)
- Years since graduation
- 50
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 72
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1976Medical school: Boston University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
FL license ME 89747
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Jackson Health System Miami, FL
Medical groups
- University of Miami (2,377 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 72
- Services billed
- 115
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 89 | 43 |
| Established patient office or other outpatient visit, 30-39 minutes | 45 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Miami, FL | 40 |
| Ofev (nintedanib esylate) | 32 |
| Mycophenolate Mofetil Other prescribers in Miami, FL | 27 |
| Prednisone Other prescribers in Miami, FL | 22 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Miami, FL | 21 |
| Pirfenidone | 19 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Miami, FL | 16 |
| Amoxicillin-Clavulanate Potass (amoxicillin/potassium clav) Other prescribers in Miami, FL | 14 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Miami, FL | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $35,157 in research payments for these studies, mostly to the institutions running them.
- A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SAR…
Boehringer Ingelheim Pharmaceuticals, Inc. - Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Cumberland Pharmaceuticals, Inc. · Recruiting · NCT05571059 - A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SAR…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.